Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MBX Biosciences, Inc.MBX · Entity 4247 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MBX Biosciences, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.91 · Expires 2036-06-04 | Direct | 12,500 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Grant · Acquired 12,500 · Balance 12,500 F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company. |
| Common StockSEC Table I · non-derivative | Direct | 24,329 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 24,329 |
Filing footnotes · ownership attribution and instrument terms
F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 11:59 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $30.91 | $0.00 |
DisclosureSEC source: 0001193125-26-258436 · ownership.xml · derivative · entry 2 Pescovitz Ora H. · CIK 0001519624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-06-04 F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 12:01 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock option (right to buy) · Derivative | 16,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0000950170-25-082698 · ownership.xml · derivative · entry 1 Pescovitz Ora H. · CIK 0001519624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 12:39 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | PurchaseCommon Stock | 7,693 | $5.89 | $45,311.77 |
DisclosureSEC source: 0000950170-25-052685 · ownership.xml · nonDerivative · entry 1 Pescovitz Ora H. · CIK 0001519624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,329 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.65 to $6.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:00 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock Option (Right to Buy) · Derivative | 15,963 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-106431 · ownership.xml · derivative · entry 1 Pescovitz Ora H. · CIK 0001519624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,963 Underlying: Common Stock · 15,963 shares Expires 2034-09-11 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.